Zhejiang Agr & For University

Zhejiang Agr & For University

Search term
Advanced Search Citation Search
Search term
Advanced Search Citation Search

Hematological Oncology

Volume 26, Issue 2 pp. 115-122

Current Awareness

Current Awareness in Hematological Oncology

First published: 28 May 2008

https://doi.org/10.1002/hon.831

Share a link

Email
Wechat
Bluesky

Abstract

In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Reviews; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non-Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

Current Awareness

1. Reviews
Google Scholar
Aleman BMP, Van Leeuwen FE. Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment?. Hematol Oncol Clin North Am (2007) 21: 961
10.1016/j.hoc.2007.07.005
PubMed Web of Science® Google Scholar
Alibhai SMH, Leach M, Kermalli H, Gupta V, Kowgier ME, Tomlinson GA, Brandwein J, Buckstein R, Minden MD. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol (2007) 64: 19
10.1016/j.critrevonc.2007.07.003
PubMed Web of Science® Google Scholar
Anderson VR, Perry CM. Fludarabine - A review of its use in non-Hodgkin's lymphoma. Drugs (2007) 67: 1633
10.2165/00003495-200767110-00008
CAS PubMed Web of Science® Google Scholar
Apostolidou E, Swords R, Alvarado Y, Giles FJ. Treatment of acute lymphoblastic leukemia - A new era. Drugs (2007) 67: 2153
10.2165/00003495-200767150-00004
CAS PubMed Web of Science® Google Scholar
Bjorkstrand B, Gahrton G. High-dose treatment with autologous stem cell transplantation in multiple myeloma: Past, present and future. Semin Hematol (2007) 44: 227
10.1053/j.seminhematol.2007.08.010
PubMed Web of Science® Google Scholar
Boleti E, Johnson PWM. Primary mediastinal B-cell lymphoma. Hematol Oncol (2007) 25: 157
10.1002/hon.818
CAS PubMed Web of Science® Google Scholar
Breems DA, Lowenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol (2007) 44: 259
10.1053/j.seminhematol.2007.08.002
PubMed Web of Science® Google Scholar
Brepoels L, Stroobants S. Is [¹⁸F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?. Hematol Oncol Clin North Am (2007) 21: 855
10.1016/j.hoc.2007.07.003
PubMed Web of Science® Google Scholar
Canellos GP. Relapsed and refractory Hodgkin's lymphoma: New avenues?. Hematol Oncol Clin North Am (2007) 21: 929
10.1016/j.hoc.2007.06.012
PubMed Web of Science® Google Scholar
Cartron G, Solal-Celigny P. Maintenance therapy for low-grade lymphomas: Has the time come?. Curr Opin Oncol (2007) 19: 425
10.1097/CCO.0b013e3282c9ad65
CAS PubMed Web of Science® Google Scholar
Cashen AF, Bartlett NL. Therapy of relapsed Hodgkin lymphoma. Blood Rev (2007) 21: 233
10.1016/j.blre.2007.06.001
CAS PubMed Web of Science® Google Scholar
Cheson BD. The international harmonization project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am (2007) 21: 841
10.1016/j.hoc.2007.06.011
PubMed Web of Science® Google Scholar
Chiriva-Internati M, Cobos E, Kast WM. Advances in immunotherapy of multiple myeloma: From the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol (2007) 26: 197
10.1080/08830180701365966
CAS PubMed Web of Science® Google Scholar
Cotta CV, Bueso-Ramos CE. New insights into the pathobiology and treatment of chronic myelogenous leukemia. Ann Diagn Pathol (2007) 11: 68
10.1016/j.anndiagpath.2006.12.002
PubMed Web of Science® Google Scholar
De Witte T, Suciu S, Brand R, Muus P, Kroger N. Autologous stem cell transplantation in myelodysplastic syndromes. Semin Hematol (2007) 44: 274
10.1053/j.seminhematol.2007.08.006
PubMed Web of Science® Google Scholar
Diehl V, Engert A, Re D. New strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hematol Oncol Clin North Am (2007) 21: 897
10.1016/j.hoc.2007.07.004
PubMed Web of Science® Google Scholar
Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies. Ann Oncol (2007) 18: 71
10.1093/annonc/mdm297
Web of Science® Google Scholar
Dreger P, Brand R, Michallet M. Autologous stem cell transplantation for chronic lymphocytic leukemia. Semin Hematol (2007) 44: 246
10.1053/j.seminhematol.2007.08.008
PubMed Web of Science® Google Scholar
Eichhorst B, Hallek M. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol (2007) 20: 469
10.1016/j.beha.2007.02.002
PubMed Web of Science® Google Scholar
Fernandez HF, Escalon MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: Are we on the right road?. Bone Marrow Transplant (2007) 40: 505
10.1038/sj.bmt.1705744
CAS PubMed Web of Science® Google Scholar
Frankfurt O, Licht JD, Tallman MS. Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol (2007) 19: 635
10.1097/CCO.0b013e3282f10e55
PubMed Web of Science® Google Scholar
Gine E, Moreno C, Esteve J, Montserrat E. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. Best Pract Res Clin Haematol (2007) 20: 529
10.1016/j.beha.2007.03.002
CAS PubMed Web of Science® Google Scholar
Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol (2007) 157: 433
10.1111/j.1365-2133.2007.07975.x
CAS PubMed Web of Science® Google Scholar
Grever MR, Lucas DM, Johnson AJ, Byrd JC. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol (2007) 20: 545
10.1016/j.beha.2007.03.005
CAS PubMed Web of Science® Google Scholar
Gribben JG. Stem-cell transplantation in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol (2007) 20: 513
10.1016/j.beha.2007.03.003
CAS PubMed Web of Science® Google Scholar
Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol (2007) 20: 455
10.1016/j.beha.2007.02.001
CAS PubMed Web of Science® Google Scholar
Hart DP, Peggs KS. Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies. Clin Pharmacol Ther (2007) 82: 325
10.1038/sj.clpt.6100283
CAS PubMed Web of Science® Google Scholar
Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG. Novel therapies in myeloma. Curr Opin Hematol (2007) 14: 609
10.1097/MOH.0b013e3282f0e948
CAS PubMed Web of Science® Google Scholar
Hochhaus A. Advances in the treatment of haematological malignancies: Optimal sequence of CML treatment. Ann Oncol (2007) 18: 58
PubMed Web of Science® Google Scholar
Hoppe RT. Hodgkin's lymphoma: The role of radiation in the modern combined strategies of treatment. Hematol Oncol Clin North Am (2007) 21: 915
10.1016/j.hoc.2007.06.013
PubMed Web of Science® Google Scholar
Horwitz SM. Management of peripheral T-cell non-Hodgkin's lymphoma. Curr Opin Oncol (2007) 19: 438
10.1097/CCO.0b013e3282ce6f8f
PubMed Web of Science® Google Scholar
Hunter T. Treatment for chronic myelogenous leukemia: The long road to imatinib. J Clin Invest (2007) 117: 2036
10.1172/JCI31691
CAS PubMed Web of Science® Google Scholar
Kaspers GJL, Zwaan CN. Pediatric acute myeloid leukemia: Towards high-quality cure of all patients. Haematologica (2007) 92: 1519
10.3324/haematol.11203
PubMed Web of Science® Google Scholar
Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia. Leukemia (2007) 21: 1885
10.1038/sj.leu.2404802
CAS PubMed Web of Science® Google Scholar
Kharfan-Dabaja MA, Abou Mourad YR, Fernandez HF, Pasquini MC, Santos ES. Hematopoietic cell transplantation in acute promyelocytic leukemia: A comprehensive review. Biol Blood Marrow Transplant (2007) 13: 997
10.1016/j.bbmt.2007.05.005
PubMed Web of Science® Google Scholar
Kharfan-Dabaja MA, Kumar A, Behera M, Djulbegovic B. Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukemia: What is the published evidence?. Br J Haematol (2007) 139: 234
10.1111/j.1365-2141.2007.06773.x
CAS PubMed Web of Science® Google Scholar
King ME, Rowe JM. Recent developments in acute myelogenous leukemia therapy. Oncologist (2007) 12: 14
10.1634/theoncologist.12-S2-14
CAS PubMed Web of Science® Google Scholar
Kiss TL, Sabry W, Lazarus HM, Lipton JH. Blood and marrow transplantation in elderly acute myeloid leukaemia patients - Older certainly is not better. Bone Marrow Transplant (2007) 40: 405
10.1038/sj.bmt.1705747
CAS PubMed Web of Science® Google Scholar
Ludwig H, Strasser-Weippl K, Schreder M, Zojer N. Advances in the treatment of hematological malignancies: Current treatment approaches in multiple myeloma. Ann Oncol (2007) 18: 64
10.1093/annonc/mdl341
CAS PubMed Web of Science® Google Scholar
Macdonald DA, Connors JM. New strategies for the treatment of early stages of Hodgkin's lymphoma. Hematol Oncol Clin North Am (2007) 21: 871
10.1016/j.hoc.2007.06.014
PubMed Web of Science® Google Scholar
Matutes E. Differential diagnosis in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol (2007) 20: 367
10.1016/j.beha.2007.03.001
PubMed Web of Science® Google Scholar
Musto P, D'Auria F. Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Invest Drugs (2007) 16: 1467
10.1517/13543784.16.9.1467
CAS PubMed Web of Science® Google Scholar
Oakervee H, Popat R, Cavenagh JD. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. Leuk Lymphoma (2007) 48: 1910
10.1080/10428190701540991
CAS PubMed Web of Science® Google Scholar
Olavarria E. Autologous stem cell transplantation in chronic myeloid leukemia. Semin Hematol (2007) 44: 252
10.1053/j.seminhematol.2007.08.003
PubMed Web of Science® Google Scholar
Ortega J, List A. Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Curr Opin Oncol (2007) 19: 656
10.1097/CCO.0b013e3282f0e12b
CAS PubMed Web of Science® Google Scholar
Pant S, Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant (2007) 13: 877
10.1016/j.bbmt.2007.05.002
PubMed Web of Science® Google Scholar
Paolo C, Lucia F, Anna D. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. Leuk Lymphoma (2007) 48: 1496
10.1080/10428190701435275
CAS PubMed Web of Science® Google Scholar
Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol (2007) 14: 632
10.1097/MOH.0b013e3282efb17c
PubMed Web of Science® Google Scholar
Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma (2007) 48: 1472
10.1080/10428190701471981
CAS PubMed Web of Science® Google Scholar
Prakash S, Swerdlow SH. Nodal aggressive B-cell lymphomas: A diagnostic approach. J Clin Pathol (2007) 60: 1076
10.1136/jcp.2006.039263
PubMed Web of Science® Google Scholar
Prince HM, Adena M, Smith DK, Hertel J. Efficacy of single-agent bortezomib vs single-agent thalidomide in patients with relapsed or refractory multiple myeloma: A systematic comparison. Eur J Haematol (2007) 79: 93
10.1111/j.1600-0609.2007.00886.x
CAS PubMed Web of Science® Google Scholar
Quach H, Prince HM, Mileshkin L. Treatment strategies in elderly patients with multiple myeloma. Drug Aging (2007) 24: 829
10.2165/00002512-200724100-00004
Web of Science® Google Scholar
Rao KV. Lenalidomide in the treatment of multiple myeloma. Am J Health Syst Pharm (2007) 64: 1799
10.2146/ajhp070029
CAS PubMed Web of Science® Google Scholar
Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acute myeloid leukemia. Cancer (2007) 110: 1900
10.1002/cncr.23000
CAS PubMed Web of Science® Google Scholar
Schmitz N, Dreger P, Glass B, Sureda A. Allogeneic transplantation in lymphoma: Current status. Haematologica (2007) 92: 1533
10.3324/haematol.11185
PubMed Web of Science® Google Scholar
Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol (2007) 44: 234
10.1053/j.seminhematol.2007.08.007
PubMed Web of Science® Google Scholar
Specht L, Raemaekers J. Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?. Hematol Oncol Clin North Am (2007) 21: 881
10.1016/j.hoc.2007.07.002
PubMed Web of Science® Google Scholar
Sureda A. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma. Hematol Oncol Clin North Am (2007) 21: 943
10.1016/j.hoc.2007.07.008
PubMed Web of Science® Google Scholar
Takahashi S. Leukemia: Cord blood for allogeneic stem cell transplantation. Curr Opin Oncol (2007) 19: 667
10.1097/CCO.0b013e3282f0e1a1
PubMed Web of Science® Google Scholar
Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol (2007) 20: 479
10.1016/j.beha.2007.02.004
CAS PubMed Web of Science® Google Scholar
Tward J, Glenn M, Pulsipher M, Barnette P, Gaffney D. Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leuk Lymphoma (2007) 48: 1482
10.1080/10428190701447346
PubMed Web of Science® Google Scholar
Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol (2007) 19: 660
10.1097/CCO.0b013e3282f0e188
PubMed Web of Science® Google Scholar
Willemze R, Labar B. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: Is there a role for autologous stem cell transplantation?. Semin Hematol (2007) 44: 267
10.1053/j.seminhematol.2007.08.004
PubMed Web of Science® Google Scholar
Wong BY, Gregory SA, Dang NH. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest (2007) 25: 495
10.1080/07357900701360096
CAS PubMed Web of Science® Google Scholar
2. General
Google Scholar
Ferra C, Marcos P, Misis M, Morgades M, Bordeje ML, Oriol A, Lloveras N, Sancho JM, Xicoy B, Batlle M, Klamburg J, Feliu E, Ribera JM. Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: A single-center experience. Int J Hematol (2007) 85: 195
10.1532/IJH97.E0625
PubMed Web of Science® Google Scholar
Gojo I, Tidwell ML, Greer J, Takebe N, Seiter K, Pochron MF, Johnson B, Sznol M, Karp JE. Phase I and pharmacokinetic study of Triapine®, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res (2007) 31: 1165
10.1016/j.leukres.2007.01.004
CAS PubMed Web of Science® Google Scholar
Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, Gomez-Codina J, Salar A, Bailen A, Ribera JM, Lopez A, Briones J, Munoz A, Encuentra M, De Sevilla AF. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica (2007) 92: 1489
10.3324/haematol.11360
CAS PubMed Web of Science® Google Scholar
Izaki S, Goto H, Okuda K, Matsuda M, Watanabe Y, Fujioka K, Hanzawa N, Sumita H, Takahashi H, Goto S, Kai S, Sekiguchi H, Funabiki T, Sasaki H, Ikuta K, Yokota S. Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. Int J Hematol (2007) 86: 253
10.1007/BF03006930
PubMed Web of Science® Google Scholar
Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemia. Blood (2007) 110: 1762
10.1182/blood-2007-03-081364
CAS PubMed Web of Science® Google Scholar
Luminari S, Cesaretti M, Rashid I, Mammi C, Montanini A, Barbolini E, Bellei M, Pennese E, Sirotti MA, Marcheselli L, Partesotti G, Bari A, Maiorana A, Bonacorsi G, Federico M. Incidence, clinical characteristics and survival of malignant lymphomas: A population-based study from a cancer registry in northern Italy. Hematol Oncol (2007) 25: 189
10.1002/hon.826
CAS PubMed Web of Science® Google Scholar
Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res (2007) 31: 751
10.1016/j.leukres.2006.11.013
PubMed Web of Science® Google Scholar
Yanada M, Narimatsu H, Suzuki T, Matsuo K, Naoe T. Randomized controlled trials of treatments for hematologic malignancies - Study characteristics and outcomes. Cancer (2007) 110: 334
10.1002/cncr.22776
CAS PubMed Web of Science® Google Scholar
Leukemias: 3. Lymphoblastic
Google Scholar
Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, Soler G, Ballerini P, Thomas X, Soulier J, Dombret H, Macintyre EA, Asnafi V. Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood (2007) 110: 2324
10.1182/blood-2007-04-079988
CAS PubMed Web of Science® Google Scholar
Sirvent N, Suciu S, Bertrand Y, Uyttebroeck A, Lescoeur B, Otten J. Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: Results of the EORTC CLG study 58881. Pediatr Blood Cancer (2007) 49: 344
10.1002/pbc.20716
PubMed Web of Science® Google Scholar
Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE, Mahotka C, Dilloo D. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica (2007) 92: 1043
10.3324/haematol.10675
CAS PubMed Web of Science® Google Scholar
Treatment
Google Scholar
Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, Pullen J, Pettenati MJ, Carroll AJ, Shuster JJ, Camitta B. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from Children's Oncology Group Study P9201. Blood (2007) 110: 1105
10.1182/blood-2006-12-061689
CAS PubMed Web of Science® Google Scholar
Choi S, Henderson MJ, Kwan E, Beesley AH, Sutton R, Bahar AY, Giles J, Venn NC, Dalla Pozza L, Baker DL, Marshall GM, Kees UR, Haber M, Norris MD. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood (2007) 110: 632
10.1182/blood-2007-01-067785
CAS PubMed Web of Science® Google Scholar
Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia (2007) 21: 2240
10.1038/sj.leu.2404866
CAS PubMed Web of Science® Google Scholar
Flotho C, Coustan-Smith E, Pei DQ, Cheng C, Song GC, Pui CH, Downing JR, Campana D. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 110: 1271
10.1182/blood-2007-01-068478
CAS PubMed Web of Science® Google Scholar
Hafez M, Al-Tonbary Y, El-Bayoumi MA, Hatem N, Hawas S, Mansour A, Marzouk I, Hafez MM, Yahia S, Farahat N. Markers of apoptosis and proliferation related gene products as predictors of treatment outcome in childhood acute lymphoblastic leukemia. Hematology (2007) 12: 209
10.1080/10245330701214384
CAS PubMed Web of Science® Google Scholar
Howell DL, Lew G, Comeaux LG, Meacham LR. Late effects risk profiles using the long-term follow-up guidelines in identical twin survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer (2007) 49: 349
10.1002/pbc.20835
PubMed Web of Science® Google Scholar
Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ, Dastugue N, Schrappe M, Pui CH, Basso G, Silverman LB, Janka-Schaub GE. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 110: 1112
10.1182/blood-2006-07-038299
CAS PubMed Web of Science® Google Scholar
Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood (2007) 110: 2309
10.1182/blood-2007-02-073528
CAS PubMed Web of Science® Google Scholar
Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Bruck P, Hoelzer D, Ottmann OG. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ ALL). Blood (2007) 110: 727
10.1182/blood-2006-11-052373
CAS PubMed Web of Science® Google Scholar
Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, Kubicka M, Koltan S, Koltan A, Pogorzala M, Kurylak A, Olszewska-Slonina D, Balwierz W, Juraszewska E, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Malinowska I, Stanczak E, Wachowiak J, Konatkowska B, Gil L, Balcerska A, Maciejka-Kapuscinska L. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol (2007) 133: 875
10.1007/s00432-007-0274-1
CAS PubMed Web of Science® Google Scholar
Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lheritier V, Vernant JP, Dombret H, Thomas X. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia (2007) 21: 1907
10.1038/sj.leu.2404824
CAS PubMed Web of Science® Google Scholar
Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, Kosaka Y, Oda T, Oda M, Hayashi Y, Eguchi M, Horibe K, Nakahata T, Mizutani S, Ishii E. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: A final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia (2007) 21: 2258
10.1038/sj.leu.2404903
CAS PubMed Web of Science® Google Scholar
Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ. Allergic reactions to E. coli L-asparaginase do not effect outcome in childhood B-precursor acute lymphoblastic leukemia - A Children's Oncology Group study. J Pediatr Hematol Oncol (2007) 29: 627
10.1097/MPH.0b013e3181483df1
CAS PubMed Web of Science® Google Scholar
4. Myeloid & Myelodysplastic Syndromes
Google Scholar
Lee CY, Tien HF, Hu CY, Chou WC, Lin LI. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukemia. Br J Cancer (2007) 97: 877
10.1038/sj.bjc.6603966
CAS PubMed Web of Science® Google Scholar
Li X, Sun WJ, Li ZJ, Zhao YZ, Li YT, Li Y, Wan CC, Li QC, Yang RC, Han MZ, Wnag JX, Qiu LG. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center. Leuk Res (2007) 31: 765
10.1016/j.leukres.2006.07.028
PubMed Web of Science® Google Scholar
Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 25: 3503
10.1200/JCO.2006.08.5696
PubMed Web of Science® Google Scholar
Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrozek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol (2007) 25: 3337
10.1200/JCO.2007.10.8720
CAS PubMed Web of Science® Google Scholar
Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favourable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood (2007) 110: 1262
10.1182/blood-2006-04-015826
CAS PubMed Web of Science® Google Scholar
Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, Kessler T, Buchner T, Berdel WE, Mesters RM. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia (2007) 21: 1901
10.1038/sj.leu.2404820
CAS PubMed Web of Science® Google Scholar
Sung KW, Choi J, Hwang YK, Lee SJ, Kim HJ, Lee SH, HeeYbo K, Jung HL, Koo HH. Overexpression of apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin Cancer Res (2007) 13: 5109
10.1158/1078-0432.CCR-07-0693
CAS PubMed Web of Science® Google Scholar
Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 110: 1025
10.1182/blood-2006-12-061283
CAS PubMed Web of Science® Google Scholar
Treatment
Google Scholar
Blum W, Klisovic RB, Hackanson B, Liu ZF, Liu SJ, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 25: 3884
10.1200/JCO.2006.09.4169
CAS PubMed Web of Science® Google Scholar
Han HS, Rybicki LA, Thiel K, Kalaycio ME, Sobecks R, Advani A, Brown S, Sekeres MA. White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leuk Lymphoma (2007) 48: 1561
10.1080/10428190701474373
PubMed Web of Science® Google Scholar
Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res (2007) 13: 4467
10.1158/1078-0432.CCR-07-0381
CAS PubMed Web of Science® Google Scholar
Knipp S, Hildebrand B, Kundgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer (2007) 110: 345
10.1002/cncr.22779
CAS PubMed Web of Science® Google Scholar
Manoharan A, Reynolds J, Matthews J, Baxter H, Di Iulio J, Leahy M, Juneja S. Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia - A multicentre, phase II study. Drugs Aging (2007) 24: 481
10.2165/00002512-200724060-00004
PubMed Web of Science® Google Scholar
Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood (2007) 110: 2302
10.1182/blood-2007-03-078576
CAS PubMed Web of Science® Google Scholar
Yamauchi T, Negoro E, Arai H, Ikegaya S, Takagi K, Takemura H, Inai K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T. Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Anticancer Res (2007) 27: 2635
PubMed Web of Science® Google Scholar
5. Chronic
Google Scholar
Treatment
Google Scholar
Branford S, Hughes T, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α. Cancer (2007) 110: 801
10.1002/cncr.22842
CAS PubMed Web of Science® Google Scholar
Carella AM, Lerma E. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol (2007) 86: 749
10.1007/s00277-007-0326-2
PubMed Web of Science® Google Scholar
Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J. Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukemia. PharmacoEconomics (2007) 25: 481
10.2165/00019053-200725060-00004
CAS PubMed Web of Science® Google Scholar
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 117: 2408
10.1172/JCI31095
CAS PubMed Web of Science® Google Scholar
Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Blonski JZ. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol (2007) 79: 107
10.1111/j.1600-0609.2007.00889.x
CAS PubMed Web of Science® Google Scholar
Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: Results of the EPIC study. Leukemia (2007) 21: 2287
10.1038/sj.leu.2404858
CAS PubMed Web of Science® Google Scholar
6. Others
Google Scholar
Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol (2007) 118: 178
10.1159/000109470
PubMed Web of Science® Google Scholar
Kim SJ, Kim JY, Cho YJ, Seo BK, Kim BS. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol (2007) 37: 382
10.1093/jjco/hym037
PubMed Web of Science® Google Scholar
Lymphomas: 7. Hodgkin's
Google Scholar
Diepstra A, Van Imhoff GW, Karim-Kos HE, Van den Berg A, Te Meerman GJ, Niens M, Nolte IM, Bastiaannet E, Schaapveld M, Vellenga E, Poppema S. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol (2007) 25: 3101
10.1200/JCO.2006.10.0917
PubMed Web of Science® Google Scholar
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol (2007) 25: 3746
10.1200/JCO.2007.11.6525
CAS PubMed Web of Science® Google Scholar
Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K, Daw S, Hewitt M, Wallace WH, Shankar A. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - A Children's Cancer and Leukaemia Group report. Br J Haematol (2007) 138: 761
10.1111/j.1365-2141.2007.06736.x
CAS PubMed Web of Science® Google Scholar
Hjalgrim H, Ekstrom-Smedby K, Rostgaard K, Amini RM, Molin D, Hamilton-Dutoit S, Schollkopf C, Chang ET, Ralfkiaer E, Adami HO, Glimelius B, Melbye M. Cigarette smoking and risk of Hodgkin lymphoma: A population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 16: 1561
10.1158/1055-9965.EPI-07-0094
CAS PubMed Web of Science® Google Scholar
Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D'Alo F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol (2007) 18: 1376
10.1093/annonc/mdm132
CAS PubMed Web of Science® Google Scholar
Valsami S, Pappa V, Rontogianni D, Kontsioti F, Papageorgiou E, Dervenoulas J, Karmiris T, Papageorgiou S, Harhalakis N, Xiros N, Nikiforakis E, Economopoulos T. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: A potential prognostic role of MUM1/IRF4. Haematologica (2007) 92: 1343
10.3324/haematol.11523
CAS PubMed Web of Science® Google Scholar
Zsofia M, Katalin K, Judit V, Gyorgy S, Arpad I. What is the price of survival in Hodgkin's lymphoma? Long-term follow-up of cured patients. Hematol Oncol (2007) 25: 178
10.1002/hon.824
PubMed Web of Science® Google Scholar
Treatment
Google Scholar
Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol (2007) 25: 3902
10.1200/JCO.2007.11.9867
PubMed Web of Science® Google Scholar
Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, Van Besien K, Zelenetz AD, Cheson BD, Canellos GP. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 18: 1071
10.1093/annonc/mdm090
CAS PubMed Web of Science® Google Scholar
Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G. Hodgkin's lymphoma: Response assessment by revised International Workshop Criteria. Leuk Lymphoma (2007) 48: 1539
10.1080/10428190701422414
PubMed Web of Science® Google Scholar
Eich HT, Gossmann A, Engert A, Kriz J, Bredenfeld H, Hansemann K, Skripnitchenko R, Brillant C, Pfistner B, Staar S, Diehl V, Muller RP. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma - Analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys (2007) 69: 1187
10.1016/j.ijrobp.2007.04.035
PubMed Web of Science® Google Scholar
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfeundschuh M, Sieber M, Tesch H, Franke A, Koch P, De Wit M, Paulus U, Hasenclever D, Loeffler M, Muller RP, Muller-Hermelink HK, Duhmke E, Diehl V. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol (2007) 25: 3495
10.1200/JCO.2006.07.0482
CAS PubMed Web of Science® Google Scholar
Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma (2007) 48: 1721
10.1080/10428190701559140
PubMed Web of Science® Google Scholar
8. Non-Hodgkin's
Google Scholar
Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, Turner AR, Reiman T. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood (2007) 110: 1278
10.1182/blood-2007-01-070300
CAS PubMed Web of Science® Google Scholar
Herishanu Y, Perry C, Braunstein R, Metser U, Goor O, Rogowski O, Berliner S, Polliack A, Naparstek E. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. Eur J Haematol (2007) 79: 150
10.1111/j.1600-0609.2007.00894.x
CAS PubMed Web of Science® Google Scholar
Kim SJ, Kim BS, Choi CW, Choi J, Kim I, Lee YH, Kim JS. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol (2007) 18: 1382
10.1093/annonc/mdm183
CAS PubMed Web of Science® Google Scholar
Klapper W, Hoster E, Rolver L, Schrader C, Janssen D, Tiemann M, Bernd HW, Determann O, Hansmann ML, Moller P, Feller A, Stein H, Wacker HH, Dreyling M, Unterhalt M, Hiddemann W, Ott G. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: The German Low Grade Lymphoma Study Group. J Clin Oncol (2007) 25: 3330
10.1200/JCO.2006.10.5833
PubMed Web of Science® Google Scholar
Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, Loong S, Tao M. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol (2007) 79: 132
10.1111/j.1600-0609.2007.00878.x
CAS PubMed Web of Science® Google Scholar
Linderoth J, Ehinger M, Jerkeman M, Bendahl PO, Akerman M, Berglund M, Enblad G, Erlanson M, Roos G, Cavallin-Stahl E. CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. Leuk Lymphoma (2007) 48: 1774
10.1080/10428190701494520
CAS PubMed Web of Science® Google Scholar
Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadie M, Spinelli JJ, Costantini AS, Rudiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood (2007) 110: 695
10.1182/blood-2006-11-051672
CAS PubMed Web of Science® Google Scholar
Nogami M, Nakamoto Y, Sakamoto S, Fukushima K, Okada T, Saga T, Higashi T, Senda M, Matsui T, Sugimura K. Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann Nucl Med (2007) 21: 189
10.1007/s12149-007-0015-1
PubMed Web of Science® Google Scholar
Park YH, Kim WS, Bange SM, Lee S, Uhm JE, Yang SH, Lee SS, Park K, Ko YH, Ryoo BY. What is stage II in high-grade primary gastric lymphoma? How to define the range of “localized disease”. Leuk Res (2007) 31: 1039
10.1016/j.leukres.2006.08.021
PubMed Web of Science® Google Scholar
Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol (2007) 18: 1209
10.1093/annonc/mdm110
CAS PubMed Web of Science® Google Scholar
Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Miller TP, Grogan TM, Rimsza LM. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest (2007) 87: 979
10.1038/labinvest.3700665
CAS PubMed Web of Science® Google Scholar
Treatment
Google Scholar
Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G. Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by integrated International Workshop Criteria. Leuk Lymphoma (2007) 48: 1522
10.1080/10428190701474365
PubMed Web of Science® Google Scholar
Busse A, Hutter G, Siehl JM, Schmittel A, Thiel E, Keilholz U. A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high-grade non-Hodgkins lymphoma. Leuk Lymphoma (2007) 48: 1755
10.1080/10428190701534432
CAS PubMed Web of Science® Google Scholar
Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, Vande Ven C, Perkins SL, Cairo MS. A phase I study of ⁹⁰yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: A Children's Oncology Group study. Clin Cancer Res (2007) 13: 5652S
10.1158/1078-0432.CCR-07-1060
CAS PubMed Web of Science® Google Scholar
Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol (2007) 138: 502
10.1111/j.1365-2141.2007.06684.x
CAS PubMed Web of Science® Google Scholar
Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma (2007) 48: 1712
10.1080/10428190701493902
CAS PubMed Web of Science® Google Scholar
El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch I, Reyes F, Haioun C. Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol (2007) 18: 1363
10.1093/annonc/mdm133
CAS PubMed Web of Science® Google Scholar
El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I. T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: Report on 61 patients and review of literature. Leuk Lymphoma (2007) 48: 1764
10.1080/10428190701559124
PubMed Web of Science® Google Scholar
Fabbri A, Lenoci M, Gozzetti A, Chitarrelli I, Olcese F, Raspadori D, Gobbi M, Lauria F. Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol (2007) 139: 90
10.1111/j.1365-2141.2007.06746.x
CAS PubMed Web of Science® Google Scholar
Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, Gianelli U, Maiorana A, Merli F, Bellei M, Pozzi S, Stelitano C, Lazzaro A, Gobbi PG, Baldini L, Bergantini S, Fregoni V, Brugiatelli M. Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. Haematologica (2007) 92: 1482
10.3324/haematol.11502
CAS PubMed Web of Science® Google Scholar
Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, Paganelli G. High activity ⁹⁰Y-ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br J Haematol (2007) 139: 590
10.1111/j.1365-2141.2007.06869.x
CAS PubMed Web of Science® Google Scholar
Fina M, Tani M, Stefoni V, Musuraca G, Marchi E, Pellegrini C, Alinari L, Derenzini E, Bacci F, Pileri S, Baccarani M, Zinzani PL. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leuk Lymphoma (2007) 48: 2167
10.1080/10428190701642102
CAS PubMed Web of Science® Google Scholar
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Grappo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood (2007) 110: 2316
10.1182/blood-2007-02-074641
CAS PubMed Web of Science® Google Scholar
Hindorf C, Emfietzoglou D, Linen O, Bousis C, Fotopoulos A, Kostarelos K, Flux GD. Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread. Cancer Biother Radiopharm (2007) 22: 357
10.1089/cbr.2007.347
CAS PubMed Web of Science® Google Scholar
Isobe K, Kagami Y, Higuchi K, Kodaira T, Hasegawa M, Shikama N, Nakazawa M, Fukuda I, Nihei K, Ito K, Teshima T, Matsuno Y, Oguchi M. A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: A preliminary report from the Japan Radiation Oncology Group (JAROG). Int J Radiat Oncol Biol Phys (2007) 69: 1181
10.1016/j.ijrobp.2007.04.029
PubMed Web of Science® Google Scholar
Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol (2007) 18: 1216
10.1093/annonc/mdm114
CAS PubMed Web of Science® Google Scholar
Leonard JR, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma. Clin Cancer Res (2007) 13: 6168
10.1158/1078-0432.CCR-07-0815
CAS PubMed Web of Science® Google Scholar
Li JM, Wang L, Shen Y, Xia ZG, Chen Y, Chen QS, Chen Y, Zeng XY, You JH, Qian Y, Shen ZX. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol (2007) 86: 639
10.1007/s00277-007-0320-8
CAS PubMed Web of Science® Google Scholar
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 12: 1247
10.1634/theoncologist.12-10-1247
CAS PubMed Web of Science® Google Scholar
Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 25: 3109
10.1200/JCO.2006.10.2434
CAS PubMed Web of Science® Google Scholar
Park BB, Kim JG, Sohn SK, Kang HJ, Lee SS, Eorn HS, Kwon HC, Oh SY, Kang JH, Oh SJ, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol (2007) 82: 840
10.1002/ajh.20973
CAS PubMed Web of Science® Google Scholar
Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C, Hongo JA, Gogineni A, Cole MJ, Vandlen R, Stephan JP, Young J, Chang W, Scales SJ, Ross S, Eaton D, Ebens A. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood (2007) 110: 616
10.1182/blood-2007-01-066704
CAS PubMed Web of Science® Google Scholar
Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, Bosi A. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol (2007) 25: 198
10.1002/hon.827
CAS PubMed Web of Science® Google Scholar
Rodriguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcon J, Caballero MD, De Mattos SFN, Gines J, Martinez J, Lopez A. Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma (2007) 48: 2172
10.1080/10428190701618268
CAS PubMed Web of Science® Google Scholar
Shah J, Wang W, Harrough VD, Saville W, Meredith R, Shen S, Mueh J, Lister J, Jasthy S, Maggass G, McKay C, Krumdieck R, Tharp M, Winter C, Gregory S, Buchholz W, Awasthi S, Jacobs S, Chung H, Egner J, Lobuglio AF, Forero A. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 48: 1736
10.1080/10428190701528517
CAS PubMed Web of Science® Google Scholar
Tholstrup D, Brown PD, Jurlander J, Hansen M. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. Eur J Haematol (2007) 79: 100
10.1111/j.1600-0609.2007.00877.x
CAS PubMed Web of Science® Google Scholar
Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C, Silverman DH, Witzig TE, Darif M, Molina A. Weight-based dosing of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma (2007) 7: 514
10.3816/CLM.2007.n.035
CAS PubMed Web of Science® Google Scholar
Wright J, Johnson P, Smith P, Horsman JM, Hancock BW. T cell non-Hodgkin's lymphoma: Treatment outcomes and survival in 3 large UK centres. Acta Haematol (2007) 118: 123
10.1159/000107742
PubMed Web of Science® Google Scholar
9. Plasmacytomas/Multiple Myelomas
Google Scholar
Matta GME, Battaglio S, Di Bello C, Napoli P, Baldi C, Ciccone G, Coscia M, Boccadoro M, Massaia M. Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. Clin Cancer Res (2007) 13: 5348
10.1158/1078-0432.CCR-06-2819
CAS PubMed Web of Science® Google Scholar
Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, De Coca AG, Galende J, Martin-Nunez G, Alonso JM, De las Heras N, Hernandez JM, Martin A, Lopez-Berges C, Orfao A, San Miguel JF. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood (2007) 110: 2586
10.1182/blood-2007-05-088443
CAS PubMed Web of Science® Google Scholar
Van de Velde HJK, Liu XY, Chen G, Cakana A, Deraedt W, Bayass M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica (2007) 92: 1399
10.3324/haematol.11534
PubMed Web of Science® Google Scholar
Van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 110: 827
10.1182/blood-2007-01-067728
CAS PubMed Web of Science® Google Scholar
Treatment
Google Scholar
Allegra A, Oteri G, Nastro E, Alonci A, Bellomo G, Del Fabro V, Quartarone E, Alati C, De Ponte FS, Cicciu D, Musolino C. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol (2007) 25: 164
10.1002/hon.819
CAS PubMed Web of Science® Google Scholar
Asoua N, Izuno Y, Okubo T, Ide K, Ueno H, Kawakita M, Hiroaki M, Hata H. Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma. Int J Hematol (2007) 86: 69
10.1532/IJH97.06164
PubMed Web of Science® Google Scholar
Bishton M, Gilyead M, Das Gupta E, Williams C, Russell NH, Byrne JL. High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leuk Res (2007) 31: 1063
10.1016/j.leukres.2006.12.022
CAS PubMed Web of Science® Google Scholar
Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen HM, Pang S, Bonavida B, Said J, Berenson JR. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol (2007) 138: 467
10.1111/j.1365-2141.2007.06675.x
CAS PubMed Web of Science® Google Scholar
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau J, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 357: 2123
10.1056/NEJMoa070594
CAS PubMed Web of Science® Google Scholar
Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PR. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica (2007) 92: 1505
10.3324/haematol.11435
CAS PubMed Web of Science® Google Scholar
Feyler S, Rawston A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. Br J Haematol (2007) 139: 429
10.1111/j.1365-2141.2007.06817.x
CAS PubMed Web of Science® Google Scholar
Freimann H, Calderoni A, Cornu P, Olie R. Daily practice use of bortezomib in relapsed/refractory multiple myeloma - Safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly (2007) 137: 317
CAS PubMed Web of Science® Google Scholar
Maisnar V, Radocha J, Buchler T, Blaha V, Maly J, Hajek R. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: Better response rate with earlier treatment. Eur J Haematol (2007) 79: 305
10.1111/j.1600-0609.2007.00930.x
CAS PubMed Web of Science® Google Scholar
Manochakian R, Miller KC, Chanan-Khan AA. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist (2007) 12: 978
10.1634/theoncologist.12-8-978
CAS PubMed Web of Science® Google Scholar
Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, Beshay V, Ritchie D, Simmons P, Milner AD, Zeldis JB, Prince HM. Patients with multiple myeloma treated with thalidomide: Evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57⁺ cytotoxic T cells as predictors of outcome. Haematologica (2007) 92: 1075
10.3324/haematol.11208
CAS PubMed Web of Science® Google Scholar
Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, Ishida T, Oota M, Ozaki S, Kosaka M, Sakai A, Sawamura M, Shimazaki C, Shimizu K, Takagi T, Hata H, Fukuhara T, Fujii H, Miyata A, Wakayama T, Takatsuki K. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol (2007) 79: 234
10.1111/j.1600-0609.2007.00908.x
CAS PubMed Web of Science® Google Scholar
Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol (2007) 25: 3892
10.1200/JCO.2006.10.5460
CAS PubMed Web of Science® Google Scholar
Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M. Time to first disease progression, but not β2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer (2007) 110: 824
10.1002/cncr.22855
CAS PubMed Web of Science® Google Scholar
Sharma A, Lokeshwar N, Raina V, Mohanti BK, Kumar R. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation. Natl Med J India (2007) 20: 121
PubMed Web of Science® Google Scholar
Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology (2007) 12: 235
10.1080/10245330701214236
CAS PubMed Web of Science® Google Scholar
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 357: 2133
10.1056/NEJMoa070596
CAS PubMed Web of Science® Google Scholar
Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol (2007) 82: 831
10.1002/ajh.20961
CAS PubMed Web of Science® Google Scholar
Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, Delibasi S, Kyrtsonis MC, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, Dimopoulos MA. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol (2007) 18: 1369
10.1093/annonc/mdm178
CAS PubMed Web of Science® Google Scholar
11. Bone Marrow Transplantation
Google Scholar
Akhtar S, El Weshi A, Abdelsalam M, Hussaini H, Janabi I, Rahal M, Maghfoor I. Primary refractory Hodgkin's lymphoma: Outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant (2007) 40: 651
10.1038/sj.bmt.1705792
CAS PubMed Web of Science® Google Scholar
Al-Ali HK, Brand R, Van Biezen A, Finke J, Boogaerts M, Fauser AA, Egeler M, Cahn JY, Arnold R, Biersack H, Niederwieser D, De Witte T. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia (2007) 21: 1945
10.1038/sj.leu.2404774
CAS PubMed Web of Science® Google Scholar
Benson DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res (2007) 31: 1069
10.1016/j.leukres.2006.09.021
CAS PubMed Web of Science® Google Scholar
Bergstraesser E, Hasle H, Rogge T, Fischer A, Zimmermann M, Noellke P, Niemeyer CM. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria. Pediatr Blood Cancer (2007) 49: 629
10.1002/pbc.21038
PubMed Web of Science® Google Scholar
Bolanos-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of autologous graft-versus-host disease: Results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant (2007) 13: 1185
10.1016/j.bbmt.2007.06.011
CAS PubMed Web of Science® Google Scholar
Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J, Andresen S, Koo A, Mineff V, Kalaycio M, Sweetenham JW. Patients mobilizing large numbers of CD34⁺ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant (2007) 40: 437
10.1038/sj.bmt.1705763
CAS PubMed Web of Science® Google Scholar
Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, Salles G, Feremans W, Apperley J, Samson D, Bjorkstrand B, Niederwieser D, Gahrton G, Pico JL, Goldschmidt H. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34⁺ cell selection: Long term follow-up of an EBMT phase III randomized study. Haematologica (2007) 92: 1083
10.3324/haematol.10535
PubMed Web of Science® Google Scholar
Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant (2007) 13: 1057
10.1016/j.bbmt.2007.05.012
PubMed Web of Science® Google Scholar
Campregher PV, Gooley T, Scott BL, Moravec C, Sandmaier B, Martin PJ, Deeg HJ, Warren EH, Flowers MED. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant (2007) 40: 965
10.1038/sj.bmt.1705840
CAS PubMed Web of Science® Google Scholar
Chang CK, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, Sandmaier BM, Witherspoon RP, Nash RA, Sanders JE, Bedalov A, Hansen JA, Clurman BE, Storb R, Appelbaum FR, Deeg HJ. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood (2007) 110: 1379
10.1182/blood-2007-02-076307
CAS PubMed Web of Science® Google Scholar
Chen MH, Chiou TJ, Lin PC, Gau JP, Hsu HC, Hsiao LT, Liu JH, Chen PM. Comparison of myeloblative and nonmyeloblative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. Int J Hematol (2007) 86: 275
10.1007/BF03006933
PubMed Web of Science® Google Scholar
Chim CS, Lie AKW, Liang R, Au WY, Kwong YL. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: Favorable outcome with BMT at first remission and HLA-matched unrelated donor. Bone Marrow Transplant (2007) 40: 339
10.1038/sj.bmt.1705734
CAS PubMed Web of Science® Google Scholar
Cho BS, Kim HJ, Lee S, Eom KS, Min WS, Lee JW, Kim CC. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia. Eur J Haematol (2007) 79: 170
10.1111/j.1600-0609.2007.00890.x
CAS PubMed Web of Science® Google Scholar
Cho BS, Kim YJ, Cho SG, Kim SY, Eom KS, Kim HJ, Lee S, Min CK, Kim DW, Lee JW, Min WS, Kim CC. The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome. Int J Hematol (2007) 85: 446
10.1532/IJH97.A30616
PubMed Web of Science® Google Scholar
Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scime R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome. Leukemia (2007) 21: 2316
10.1038/sj.leu.2404822
CAS PubMed Web of Science® Google Scholar
Engelhardt BG, Holland DW, Brandt SJ, Chinratanalab W, Goodman SA, Greer JP, Jagasia MH, Kassim AA, Morgan DS, Ruffner KL, Schuening FG, Wolff S, Bitting R, Sulur P, Stein RS. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes. Leuk Lymphoma (2007) 48: 1728
10.1080/10428190701534374
CAS PubMed Web of Science® Google Scholar
Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B, Rambaldi A, Morello E, Narni F, Santarone S, Locatelli F, Bacigalupo A. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: Results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol (2007) 82: 863
10.1002/ajh.20990
CAS PubMed Web of Science® Google Scholar
Ferry C, Gemayel G, Rocha V, Labopin M, Esperou H, Robin M, De Latour RP, Ribaud P, Devergie A, Leblanc T, Gluckman E, Baruchel A, Socie G. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant (2007) 40: 219
10.1038/sj.bmt.1705710
CAS PubMed Web of Science® Google Scholar
Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, Gibson J, Patton N, Bradstock K, Marks DI, Cook G. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study. Bone Marrow Transplant (2007) 40: 443
10.1038/sj.bmt.1705752
CAS PubMed Web of Science® Google Scholar
Flynn CM, Hirsch B, DeFor T, Barker JN, Miller JS, Wagner JE, Blazar BR, Burns LJ, MacMillan ML, Arora M, Weisdorf D. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis. Am J Hematol (2007) 82: 867
10.1002/ajh.20989
PubMed Web of Science® Google Scholar
Gahrton G, Iacobelli S, Bandini G, Bjorkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kroger N, Schattenberg A, Schonland SO, Verdonck LF, Volin L, De Witte T, Niederwieser D. Peripheral blood or bone marrow cells myeloablative conditioning allogeneic transplantation for multiple myeloma. Haematologica (2007) 92: 1513
10.3324/haematol.11353
PubMed Web of Science® Google Scholar
Ganguly S, Singh J, Divine CL, Deauna-Limayo D, Bodensteiner DC, Lewis JL, Curran K, Skikne BS. Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience. Leuk Res (2007) 31: 1253
10.1016/j.leukres.2006.12.021
PubMed Web of Science® Google Scholar
Gassas A, Sung L, Saunders EF, Doyle J. Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: Significantly lower relapse rate in unrelated transplantations. Bone Marrow Transplant (2007) 40: 951
10.1038/sj.bmt.1705853
CAS PubMed Web of Science® Google Scholar
Graef T, Vaupel M, Fenk R, Ruf L, Zohren F, Germing U, Haas R, Kobbe G. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. Hematol Oncol (2007) 25: 170
10.1002/hon.823
CAS PubMed Web of Science® Google Scholar
Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, De Lima M, Lichtiger B. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 40: 461
10.1038/sj.bmt.1705751
CAS PubMed Web of Science® Google Scholar
Gutierrez-Aguirre C, Gomez-Almaguer D, Cantu-Rodriguez OG, Gonzalez-Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA, Estrada-Gomez R, Gonzalez-Carrillo ML, Ruiz-Arguelles GJ. Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: Results of a multicenter study. Bone Marrow Transplant (2007) 40: 535
10.1038/sj.bmt.1705769
CAS PubMed Web of Science® Google Scholar
Gutierrez-Aguirre CH, Cantu-Rodriguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-Gonzalez O, Jaime-Perez JC, Morales-Toquero A, Tarin-Arzaga LC, Ruiz-Arguelles GJ, Gomez-Almaguer D. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology (2007) 12: 193
10.1080/10245330701214285
CAS PubMed Web of Science® Google Scholar
Hiwase D, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy (2007) 9: 539
10.1080/14653240701452800
CAS PubMed Web of Science® Google Scholar
Iori AP, Arcese W, Milano F, Calabrese E, Torelli GF, Barberi W, Mascolo MG, De Felice L, Screnci M, Lucarelli B, Malandruccolo L, Perrone MP, Salvatori S, Laurenti L, Iannella E, Ricci R, Moleti ML, Foa R. Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: A long-term follow-up. Haematologica (2007) 92: 1051
10.3324/haematol.11271
PubMed Web of Science® Google Scholar
Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, Samiee S, Chahardovali B, Alimoghaddam K, Ghaffari SH, Ghavamzadeh A. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone Marrow Transplant (2007) 40: 105
10.1038/sj.bmt.1705685
CAS PubMed Web of Science® Google Scholar
Isidori A, Motta MR, Tani M, Terragna C, Zinzani P, Curti A, Rizzi S, Taioli S, Giudice V, D'Addio A, Gugliotta G, Conte R, Baccarani M, Lemoli RM. Positive selection and transplantation of autologous highly purified CD133⁺ stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. Biol Blood Marrow Transplant (2007) 13: 1224
10.1016/j.bbmt.2007.07.004
CAS PubMed Web of Science® Google Scholar
Kalaycio M, Rybicki L, Pohlman B, Dean R, Sweetenham J, Andresen S, Sobecks R, Sekeres MA, Advani A, Brown S, Bolwell B. Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. Bone Marrow Transplant (2007) 40: 753
10.1038/sj.bmt.1705811
CAS PubMed Web of Science® Google Scholar
Kang TY, Rybicki LA, Bolwell BJ, Thakkar SG, Brown S, Dean R, Sekeres MA, Advani A, Sobecks R, Kalaycio M, Pohlman B, Sweetenham JW. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant (2007) 40: 973
10.1038/sj.bmt.1705849
CAS PubMed Web of Science® Google Scholar
Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, De Lima M. Long-term follow-up allogeneic hematopoietic stem-cell transplantation with reduced intensity conditioning for patients with chronic myeloid leukemia. Blood (2007) 110: 3456
10.1182/blood-2007-04-085969
CAS PubMed Web of Science® Google Scholar
Keeney GE, Gooley TA, Pham RN, Press OW, Pagel JM, Petersdorf SH, Maloney DG, Bensinger W, Holmberg L, Gopal AK. The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Leuk Lymphoma (2007) 48: 1961
10.1080/10428190701583983
PubMed Web of Science® Google Scholar
Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant (2007) 40: 919
10.1038/sj.bmt.1705841
CAS PubMed Web of Science® Google Scholar
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 21: 2035
10.1038/sj.leu.2404801
CAS PubMed Web of Science® Google Scholar
Kuruvilla J, Shepherd YD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant (2007) 13: 925
10.1016/j.bbmt.2007.04.006
PubMed Web of Science® Google Scholar
Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS, Kim YJ, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Shin WS, Kim CC. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: Antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2007) 13: 1083
10.1016/j.bbmt.2007.06.001
PubMed Web of Science® Google Scholar
Levenga H, Levison-Keating S, Schattenberg AV, Dolstra H, Schaap N, Raymakers RA. Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant (2007) 40: 355
10.1038/sj.bmt.1705742
CAS PubMed Web of Science® Google Scholar
Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, Tobal K, Devereux S, Pagliuca A, Mufti GJ. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol (2007) 138: 517
10.1111/j.1365-2141.2007.06676.x
CAS PubMed Web of Science® Google Scholar
Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant (2007) 40: 665
10.1038/sj.bmt.1705789
PubMed Web of Science® Google Scholar
Majhail NS, Ness KK, Burns LJ, Sun CL, Carter A, Francisco L, Forman SJ, Bhatia S, Baker KS. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study. Biol Blood Marrow Transplant (2007) 13: 1153
10.1016/j.bbmt.2007.06.003
PubMed Web of Science® Google Scholar
Martinez C, Salamero O, Arenillas L, Duque J, Lopez-Guillermo A, Rovira M, Urbano-Ispiuza A, Fernandez-Aviles F, Carreras E, Montserrat E. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution. Leuk Lymphoma (2007) 48: 1968
10.1080/10428190701573265
PubMed Web of Science® Google Scholar
Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori SI, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y. Comparable anti leukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant (2007) 13: 932
10.1016/j.bbmt.2007.04.004
PubMed Web of Science® Google Scholar
Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schoenberger S, Sinha K, Troeger A, Schmitz M, Fischer J, Gobel U, Enczmann J, Dilloo D. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant (2007) 13: 1338
10.1016/j.bbmt.2007.07.009
PubMed Web of Science® Google Scholar
Mielcarek M, Storer BE, Flowers MED, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2007) 13: 1160
10.1016/j.bbmt.2007.06.007
PubMed Web of Science® Google Scholar
Milone G, Leotta S, Battiato K, Murgano P, Mercurio S, Strano A, Poidomani M, Coppoletta S, Mauro E, Avola G, Pinto V, Camuglia MG, Giustolisi R. Intermediate dose etoposide plus G-CSF 16 µg/kg is more effective than cyclophosphamide 4 g/m² plus G-CSF 10 µg/kg in PBSC mobilization of lymphoma patients. Leuk Lymphoma (2007) 48: 1950
10.1080/10428190701573240
PubMed Web of Science® Google Scholar
Montoto S, Canals C, Rohatiner A, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister TA, Goldstone AH. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: An EBMT registry study. Leukemia (2007) 21: 2324
10.1038/sj.leu.2404850
CAS PubMed Web of Science® Google Scholar
Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton A, Buckley JD, Howells W, Gold S, Barnard DR, DeSwarte J, Kalousek D, Lange BJ, Woods WG. Autologous bone marrow transplantation for children with AML in first remission. Bone Marrow Transplant (2007) 40: 313
10.1038/sj.bmt.1705680
PubMed Web of Science® Google Scholar
Nonami A, Takenaka K, Kamezaki K, Miyamoto T, Harada N, Nagafuji K, Teshima T, Harada M. Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Int J Hematol (2007) 85: 264
10.1532/IJH97.06197
PubMed Web of Science® Google Scholar
Orsi C, Bartolozzi B, Messori A, Bosi A. Event-free survival and cost-effectiveness in adult acute lymphoblastic leukemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant (2007) 40: 643
10.1038/sj.bmt.1705790
CAS PubMed Web of Science® Google Scholar
Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol (2007) 4: 491
10.1038/ncponc0899
CAS PubMed Web of Science® Google Scholar
Ozdemir EO, Saliba RM, Champlin RE, Couriel DR, Giralt SA, De Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant (2007) 40: 125
10.1038/sj.bmt.1705699
CAS PubMed Web of Science® Google Scholar
Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol (2007) 139: 70
10.1111/j.1365-2141.2007.06759.x
CAS PubMed Web of Science® Google Scholar
Rodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernandez de Sevilla A, Bendandi M, Solano C, Leon A, Varela MR, Caballero MD. The adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica (2007) 92: 1067
10.3324/haematol.11173
PubMed Web of Science® Google Scholar
Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Stewart DA. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant (2007) 13: 814
10.1016/j.bbmt.2007.03.003
CAS PubMed Web of Science® Google Scholar
Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, Hopkins H, Hutton B, Mcdiarmid S, Huebsch LB. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant (2007) 13: 956
10.1016/j.bbmt.2007.04.009
PubMed Web of Science® Google Scholar
Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, Alyea EP, Lee SJ. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant (2007) 40: 209
10.1038/sj.bmt.1705733
CAS PubMed Web of Science® Google Scholar
Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, Nagler A. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: Fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia (2007) 21: 2109
10.1038/sj.leu.2404886
CAS PubMed Web of Science® Google Scholar
Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia (2007) 21: 1802
10.1038/sj.leu.2404781
CAS PubMed Web of Science® Google Scholar
Tiwari D, Gao F, Hidalgo J, Adkins DR, Vij R, DiPersio JF, Khoury HJ. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant (2007) 40: 671
10.1038/sj.bmt.1705795
CAS PubMed Web of Science® Google Scholar
Tobinai K, Takeyama K, Arima F, Aikawa K, Kobayashi T, Hanada S, Kasai M, Ogura M, Sueoka E, Mukai K, Tajima K, Fukuda H, Shirakawa S, Hotta T, Masanori S. Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004. Cancer Sci (2007) 98: 1350
10.1111/j.1349-7006.2007.00556.x
CAS PubMed Web of Science® Google Scholar
Unal S, Fidan G, Tavill B, Cetin M, Cetinkaya DU. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience. Pediatr Transplant (2007) 11: 645
10.1111/j.1399-3046.2007.00727.x
CAS PubMed Web of Science® Google Scholar
Veerappan R, Morrison M, Williams S, Variakojis D. Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant (2007) 40: 361
10.1038/sj.bmt.1705736
CAS PubMed Web of Science® Google Scholar
Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A, Van Lint MT, Gobbi M, Miglino M, Clavio M, Risso M, Frassoni F, Bacigalupo A. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant (2007) 40: 349
10.1038/sj.bmt.1705739
PubMed Web of Science® Google Scholar
Willemze AJ, Geskus RB, Noordijk EM, Kal HB, Egeler RM, Vossen JM. HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: Less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant (2007) 40: 319
10.1038/sj.bmt.1705729
CAS PubMed Web of Science® Google Scholar
Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W, Fyles G, Tejpar I, Loach D, Minden M, Messner H, Lipton JH. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning. Bone Marrow Transplant (2007) 40: 423
10.1038/sj.bmt.1705755
CAS PubMed Web of Science® Google Scholar
12. Cytokines
Google Scholar
Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma (2007) 7: 541
10.3816/CLM.2007.n.040
CAS PubMed Web of Science® Google Scholar
13. Diagnosis
Google Scholar
Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, Holdeman KP, Paknikar S, Armitage JO, Hankins JH. Predictive value and diagnostic accuracy of ¹⁸F-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma (2007) 48: 1548
10.1080/10428190701422059
CAS PubMed Web of Science® Google Scholar
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsens EA, Ranki A, Dummer R, Hoppe RT. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood (2007) 110: 479
10.1182/blood-2006-10-054601
CAS PubMed Web of Science® Google Scholar
Michiels JJ, De Raeve H, Hebeda K, Lam KH, Berneman Z, Schroyens W, Schwarz J. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leuk Res (2007) 31: 1031
10.1016/j.leukres.2007.01.021
CAS PubMed Web of Science® Google Scholar
Mohanty SK, Piccoli AL, Devine LJ, Patel AA, Williams GC, Winters SB, Becich MJ, Parwani AV. Synoptic tool for reporting of hematological and lymphoid neoplasms based on World Health Organization classification and College of American Pathologists checklist. BMC Cancer (2007) 7: 144
10.1186/1471-2407-7-144
PubMed Web of Science® Google Scholar
Ponzoni M, Ferreri AJM, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, Murase T, Pileri SA, Doglioni C, Zucca E, Cavalli F, Nakamura S. Definition, diagnosis, and management of intravascular large B-cell lymphoma: Proposals and perspectives from an international consensus meeting. J Clin Oncol (2007) 25: 3168
10.1200/JCO.2006.08.2313
PubMed Web of Science® Google Scholar
Rigacci L, Vitolo U, Nassi L, Merli F, Gallamini A, Pregno P, Alvarez I, Salvi F, Sancetta R, Castagnoli A, Versari A, Biggi A, Gregianin M, Pelosi E, Chisesi T, Bosi A, Levis A. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol (2007) 86: 897
10.1007/s00277-007-0356-9
PubMed Web of Science® Google Scholar
Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, Saitoh T, Handa H, Endo K, Murakami H. The usefulness of ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸FDG-PET) and a comparison of ¹⁸FDG-PET with ⁶⁷gallium scintigraphy in the evaluation of lymphoma - Relation to histologic subtypes-based on the World Health Organization classification. Cancer (2007) 110: 652
10.1002/cncr.22807
CAS PubMed Web of Science® Google Scholar
Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, Van de Loosdrecht A, Ogata K, Orfao A, Pfeilstocker M, Ruter B, Sperr WR, Stauder R, Wells DA. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 31: 727
10.1016/j.leukres.2006.11.009
PubMed Web of Science® Google Scholar
14. Cytogenetics
Google Scholar
Chang H, Trieu Y, Qi XY, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res (2007) 31: 779
10.1016/j.leukres.2006.08.002
CAS PubMed Web of Science® Google Scholar
Chang H, Ning Y, Qi XY, Yeung J, Xu W. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol (2007) 139: 51
10.1111/j.1365-2141.2007.06750.x
CAS PubMed Web of Science® Google Scholar
Deininger MWN, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer (2007) 110: 1509
10.1002/cncr.22936
PubMed Web of Science® Google Scholar
Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NCP. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood (2007) 110: 1283
10.1182/blood-2007-02-074252
CAS PubMed Web of Science® Google Scholar
Landstrom AP, Knudson RA, Dewald GW, Ketterling RP, Tefferi A. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: Clinical correlates and effect on imatinib mesylate treatment outcome. Leuk Lymphoma (2007) 48: 2137
10.1080/10428190701618284
CAS PubMed Web of Science® Google Scholar
Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen ST, Peterson LC. Chronic lymphocytic leukemia FISH panel - Impact on diagnosis. Am J Clin Pathol (2007) 128: 323
10.1309/21TN2RUWKR827UW2
PubMed Web of Science® Google Scholar
Settin A, Al Haggar M, Al Dosoky T, Al Baz R, Abdelrazik N, Fouda M, Aref S, Al-Tonbary Y. Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia. Indian J Pediatr (2007) 74: 255
10.1007/s12098-007-0040-z
PubMed Web of Science® Google Scholar
Tibiletti MG, Milani K, Martin V, Zucca E, Motta T, Cortelazzo S, Pinotti G, Mazzucchelli L, Pruneri G, Martinelli G, Barbazza R, Capella C, Bertoni F. Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type. Hematol Oncol (2007) 25: 184
10.1002/hon.825
CAS PubMed Web of Science® Google Scholar
Van den Neste E, Robin V, Francart J, Hagemeijer A, Stul M, Vandenberghe P, Delannoy A, Sonet A, Deneys V, Costantini S, Ferrant A, Robert A, Michaux L. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia (2007) 21: 1715
10.1038/sj.leu.2404764
CAS PubMed Web of Science® Google Scholar

Volume26, Issue2

June 2008

Pages 115-122

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.